XORTX Therapeutics (XRTX) Accumulated Expenses (2020 - 2021)
XORTX Therapeutics (XRTX) posted Accumulated Expenses of $230303.9 for Q4 2021, up 282.9% on a QoQ basis from $60147.9 in Q3 2021, and down 53.39% year-over-year from $494160.4 in Q4 2020.
XORTX Therapeutics (XRTX) Accumulated Expenses (2020 - 2021) Analysis & Trends
XORTX Therapeutics' Accumulated Expenses history runs 2 years deep, the most recent figure standing at $230303.9 for Q4 2021.
- Quarterly Accumulated Expenses fell 53.39% year-over-year to $230303.9 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $230303.9 (down 53.39% YoY) and the FY2021 annual result came in at $231644.9, down 51.83% from the prior year.
- Accumulated Expenses was $230303.9 for Q4 2021 at XORTX Therapeutics, up from $60147.9 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $494160.4 in Q4 2020 and bottomed at $60147.9 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 230,303.88 |
| Sep 30, 2021 | 60,147.91 |
| Dec 31, 2020 | 494,160.39 |